Slow released injection containing satraplatin and its synergist

Abstract

The slow released anticancer injection containing both satraplatin and its synergist consists of slow released microsphere and solvent. The slow released microsphere includes effective anticancer component and slow releasing supplementary material carrier, and the solvent is special solvent containing suspending agent. The effective anticancer component includes satraplatin, Cisplatin, Carboplatin, etc and satraplatin synergist selected from antitumor antibiotic, toporase inhibitor and / or tetrazine compound. The slow releasing supplementary material is selected from difatty acid-sebacic acid copolymer, polylactic acid, etc. The suspending agent is carboxymethyl cellulose sodium, etc. and has viscosity of 100-3000 cp at 20-30 deg.c. The slow released microsphere may be also prepared into slow released implanting agent for use to raising chemotherapeutic and radiotherapeutic effect.

Description

(1) Technical field

[0001] The invention relates to a sustained-release injection containing satetraplatin and / or its synergist and a preparation method thereof, belonging to the technical field of medicines. (2) Background technology

[0002] Satrapiatin (JM-216) is a third-generation platinum complex antitumor drug with a cyclohexylamine structure developed by BMS. It has a certain effect on small cell lung cancer and non-small cell lung cancer, ovarian cancer, brain tumors and head and neck tumors. However, its unexpected neurotoxicity greatly limits the application of this drug. Blood vessels, connective tissue, matrix proteins, fibrin, and collagen in the tumor stroma not only provide scaffolds and essential nutrients for the growth of tumor cells, but also affect the penetration of chemotherapy drugs around the tumor and in the tumor tissue and diffusion (see Netti et al. "The influence of the status of the extracellular matrix on the movement of drugs in solid tumor...